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Abstract
Seven classes of mitogen-activated protein kinase (MAPK)
intracellular signalling cascades exist, four of which are implicated
in breast disease and function in mammary epithelial cells. These
are the extracellular regulated kinase (ERK)1/2 pathway, the ERK5
pathway, the p38 pathway and the c-Jun N-terminal kinase (JNK)
pathway. In some forms of human breast cancer and in many
experimental models of breast cancer progression, signalling
through the ERK1/2 pathway, in particular, has been implicated as
being important. We review the influence of ERK1/2 activity on the
organised three-dimensional association of mammary epithelial
cells, and in models of breast cancer cell invasion. We assess the
importance of epidermal growth factor receptor family signalling
through ERK1/2 in models of breast cancer progression and the
influence of ERK1/2 on its substrate, the oestrogen receptor, in
this context. In parallel, we consider the importance of these
MAPK-centred signalling cascades during the cycle of mammary
gland development. Although less extensively studied, we highlight
the instances of signalling through the p38, JNK and ERK5
pathways involved in breast cancer progression and mammary
gland development.
Introduction
Four dominating mitogen-activated protein kinase (MAPK)
signalling cascades are implicated in breast disease in
mammalian cells: the extracellular regulated kinase (ERK)1/2
pathway, the c-Jun N-terminal kinase (JNK) pathway, the p38
pathway and the ERK5 pathway [1,2]. In some forms of
human breast cancer and in many experimental models of
breast cancer progression, signalling through the ERK1/2
pathway, in particular, has been implicated as being
important [3]. Signalling through each pathway involves
sequential activation of a MAPK kinase kinase (MAPKKK), a
MAPK kinase (MAPKK) and the MAPK. Considering the
ERK1/2 pathway, the primary input activator is activated Ras,
a small GTPase. It activates Raf1 (MAPKKK), which then
phosphorylates and activates MEK1/2 (MAPKK), which finally
activates ERK1/2 [1]. In its active form, ERK1/2 phosphory-
lates a wide range of protein substrates (on serine or
threonine). MAPKKKs and MAPKKs are dual Thr/Tyr kinases.
Signalling through the core to activate the MAPK is
supported on a protein scaffold [4]. However, activated
ERK1/2 is translocated from the scaffold to, for example, the
nucleus, where it phosphorylates its substrates. The activity
of the core Raf1-MEK1/2-ERK1/2 cascade is auto-regulated
by ERK1/2 inactivation of MEK1 or by ERK1/2 upregulation
of ERK1/2-specific phosphatases, for example, MKP2 and 3
(MAPK dual-specificity phosphatases) [5,6]. In this way,
ERK1/2 itself can exert control over the intensity and duration
of ERK1/2 signalling.
The ERK1/2 cascade is triggered by growth factors and
cytokines acting through receptor tyrosine kinases, G-protein-
coupled receptors, and non-nuclear activated steroid hormone
receptors [4,7-13]. ERK1/2 substrates include transcriptional
regulators, apoptosis regulators and steroid hormone
receptors (for example, oestrogen receptor (ER)α). The
biological consequences of ERK1/2 substrate phosphory-
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lation include pro-proliferative [14], pro-differentiation [14],
pro-survival [14], pro-angiogenic [15], pro-motility [16] and
pro-invasive effects [17]. We review the contribution of
MAPK signalling events to breast cancer progression as
reflected in experimental models of progression (contrasting
this to their role in normal mammary gland development).
ERK1/2 signalling in models of breast cancer
progression
In approximately 30% of human breast cancers, mutations
are found in the ERK1/2 MAPK pathway; however, the nature
of the deregulation varies between individual tumours and
cancer subtypes [18,19]. Dys-regulated ERK1/2 signalling
alone is usually not sufficient to cause cancer. Additional
mutations and changes in the expression levels of other
genes is commonly observed alongside (for example, those
encoding ErbB2 receptor, c-myc, p53 and hyaluronan-
mediated motility receptor (RHAMM)) [20,21]. Furthermore,
other major signalling networks (such as phosphoinositide 3-
kinase (PI3K)/phosphatase and tensin homolog (PTEN)/AKT)
crosstalk with ERK1/2 signalling, thereby enhancing cell
proliferation, preventing apoptosis and, in some cases,
inducing drug resistance [22]. ERK1/2 is hyper-activated in a
large subset of mammary tumours, and downstream ERK1/2
targets are also hyper-phosphorylated there [23]. There is a
trend for higher ERK1/2 activity in primary tumours of ‘node-
positive’ patients than in those from ‘node-negative’ patients,
suggesting higher ERK1/2 activity impacts metastasis [23]. A
survival analysis demonstrated that low ERK1/2 activity in
primary breast tumours is prognostic for relapse-free survival
of patients [23]. The expression and activity of ERK1/2 can
also impact a patient’s response to treatment [3,24]. Over-
expression of upstream ERK1/2 modulators (such as MEK1)
in normal mammary epithelial cells induces neoplastic trans-
formation, highlighting the relevance of this signalling network
to breast cancer [25]. Although balanced against the above
are a series of clinical studies in three cohorts of patients that
link high ERK1/2 and/or high activated (phosphorylated)
ERK1/2 levels to good disease outcome [26-28]; the
apparent contradictory nature of the two streams of data
remains to be resolved.
Immortalized mammary epithelial cell lines with normal
phenotype (including MCF10A/12A, S1, NMuMG, epH4,
human mammary epithelial cell and HB2), breast cancer cell
lines (including MCF-7, T47D, MDA-MB-231, T-42, SKBR-3,
BT549) and primary mammary epithelial cells (of both normal
and tumour origin) can be cultured and are commonly used to
model the molecular contribution of MAPK signalling in
normal epithelia and in breast cancer. We describe a range of
such studies. In addition, we present a summary in Table 1.
Sustained ERK1/2 signalling undermines epithelial cell
organisation
Primary cells and various phenotypically normal mammary
epithelial cell lines, when supported on a reconstituted base-
ment membrane (extracellular matrix (ECM)) mimic in vivo
alveolus cell organisation and form three-dimensional
spherical acini. Firstly, the outer layer of cells in contact with
the ECM polarise and exit the cell cycle. Lumen clearance
then occurs (at least in part by apoptosis) to generate the
acinus in which the mammary epithelial cells (MECs) are
organised in organotypic fashion [29]. Of particular interest is
that transformed MECs do not organise in this fashion and
their failure to do so is often determined by persistent
ERK1/2 signalling (reviewed in [30]). For instance, tumouri-
genic HMT-3522 T-42 MECs fail to organise as acini
because of a persistent β1-integrin-epidermal growth factor
receptor (EGFR)-ERK1/2 drive. However, they ‘revert’ and
form acini (like their isogenic ‘normal’ S-1 cell counterparts) if
β1-integrin, EGFR or ERK1/2 function is inhibited [31].
Importantly, this bidirectional cross-modulation of β1-integrin
and EGFR signalling via the MAPK pathway is dependent
upon a three-dimensional context. Wang and colleagues [31]
showed how partial ‘reversion’ in functional phenotype of a
range of breast cancer cells could be achieved by inhibiting
ERK1/2. A more complete ‘reversion’ was possible with
multiple signalling inhibitors (for example, of ERK1/2 plus
PI3K pathways). Thus, persistent ERK1/2 signalling contri-
butes to, but need not necessarily be the only, intracellular
signalling change that is driving loss of epithelial charac-
teristics in breast cancer cells. Finally, in breast cancer
SKBR-3 cells grown in monolayer culture, ErbB2 and ErbB3
form heterodimers, whereas in multicellular spheroids ErbB2
homodimers are formed, leading to enhanced activation of
ErbB2 and a switch in signalling pathways from PI3K to
ERK1/2 [32]. Thus, comparisons of three-dimensional and
monolayer cultures emphasise the use of three-dimensional
systems to better reflect some in vivo aspects of ErbB and
ERK1/2 signalling.
Expression of an oncogene was found to be sufficient to
impair acinus formation by normal MECs while in parallel
triggering activation of ERK1/2 signalling [33]. Persistent
activation of fibroblast frowth factor (FGF) receptor in HC11
MECs caused ERK1/2 activation, impaired acinus formation
and led to an invasive phenotype [34]. Likewise, persistent
activation of ErbB2 in MCF-10A cells, which is associated
with activation of ERK1/2, caused aberrant acinus maturation
but the cells were not invasive [35]. However, addition of
transforming growth factor (TGF)β1 induced a migratory and
invasive behaviour in these cells. Significantly, blocking
ERK1/2 activation inhibited the effect of TGFβ1 and ErbB2
on migration.
Nolan and colleagues [36] show that, in three-dimensional
assemblies, activated ErbB2 recruits the cell polarity
regulators Partitioning defect (Par)6-atypical protein kinase C
(aPKC) from their association with Par3. This disrupted cell
polarisation and caused luminal cell survival (but not
additional cell proliferation) and the formation of dysmorphic,
multi-acinar spheres. In contrast, if Par6 is over-expressed, itacts in a complex with cdc42 and aPKC to cause hyper-
proliferation and generate multi-acinar structures in an
ERK1/2-dependent fashion [36]. Thus, disrupting the cell
polarisation machinery can affect control of cell proliferation
and/or cell survival and so impact lumen clearance.
The Bcl-2 homology domain (BH3)-only pro-apoptotic
proteins Bim and Bmf (Bcl-2 modifying factor) selectively
trigger apoptosis of central cells, leading to lumen formation in
the acinus [37,38]. Oncogenes that drive luminal filling, such
as ErbB2, suppress Bim expression and drive Bim inactivation
by phosphorylation in an ERK1/2-dependent manner.
Activation of the ERK1/2 pathway is sufficient to block Bim
activity and correlates with protection from luminal apoptosis
and inhibition of lumen formation [37]. In a parallel fashion, in
pubertal mammary glands of Bim-/- mice, terminal end buds
and ducts have filled lumena, presumably due to a deficit in
pro-apoptotic signalling [39]. Thus, there is ample evidence
supporting the identification of the ERK1/2 MAPK node as a
signalling driver that must be tightly controlled if mammary
epithelial cells are to successfully organise, organotypically.
Invasion - a role for ERK1/2 signalling
Metastatic breast tumours represent the final lethal stage of
the disease, with cancer cells from the primary mammary
gland site having ‘spread’ to a secondary site (for example,
bone, lung or liver). ‘Invasive’ cells with de-regulated growth
properties and an acquired ability to degrade basement
membrane invade the local tissue environment, eventually
reaching and circulating through the lymph and vascular
systems before entering other tissues and forming secondary
tumours. Epithelial cells that have undergone an epithelial-to-
mesenchymal transition (EMT) display many of the charac-
teristics of invasive cancer cells, in that they have lost their
adhesions and polarised phenotype, have down-regulated
epithelial-specific proteins (such as tight junction
components) and have gained a proliferative and migratory/
invasive phenotype with an ability to degrade and migrate
through ECM. A range of growth factors and cytokines (for
example, human growth factor, FGF and TGFβ) have been
found to trigger EMT [40-45]. But in particular, cooperation
between TGFβ and sustained ERK1/2 signalling induces
EMT and an invasive and metastatic potential in cultured
mammary epithelial cells [40]. TGFβ signals through trans-
membrane receptor kinases and activates p38 and ERK1/2
through both Smad-dependent and Smad-independent
mechanisms and the MAPK4 pathway [46,47]. TGFβ inhibits
growth of normal epithelial cells but induces proliferation and
EMT in immortalised, phenotypically normal MCF10A cells
and in cells from advanced carcinomas [48].
During normal mammary gland development, TGFβ isoforms
seem required for pubertal ductal morphogenesis [49],
pregnancy-induced alveolar morphogenesis (in part by
mediating the action of progesterone) [49,50], for normal
transition from pregnancy to lactation and to drive involution
[51]. In pubertal mammary gland development, TGFβ inhibits
ductal growth and its role may be in sculpting the newly
developing mammary tree: branches form at sites of lowest
local TGFβ concentration [52]. Little is known of intracellular
signalling networks that support ductal branching; however,
in a pubertal mammary explant culture it was shown that
sustained ERK1/2 activation induced by TGFα caused
branching, while transient ERK1/2 activation induced by
FGF7 did not. It was hypothesised that the former would
trigger necessary matrix-metalloproteinase (MMP) expression
and the latter not [7].
Invasive cells synthesise MMPs, which degrade type IV
collagen (and other matrix components) and confer on cells
the ability to migrate and invade neighbouring tissue. ERK1/2
signalling induces MMP expression/activity, thereby impact-
ing extracellular re-modelling [53]. In breast cancer cell
cultures, invasiveness and MMP2 and MMP9 activity are
induced in response to TGFβ stimulation and ErbB2 over-
expression [54,55] and requires p38 activity in some circum-
stances. The serine protease uPA (Plasminogen activator,
Urokinase) and its receptor (uPAR) also play a crucial role in
breast cancer cell invasion and metastasis alongside MMPs.
uPA induces cell proliferation in MDA-MB-231 breast cancer
cells via ERK1/2 activation and binding of uPA to uPAR
activates ERK1/2 in MCF-7 cells [8,56]. Endogenously
produced uPA was found to be a major determinant of the
basal level of activated ERK1/2 and prevented apoptosis in
metastatic MDA-MB-231 cells [57]. ERK1/2 signalling in
MDA-MB-231 breast carcinoma cells is adapted to obtain
high urokinase expression and rapid cell proliferation; there,
inhibition of ERK1/2 activity leads to decreased cell
proliferation and decreased cyclin D1 expression [58]. In the
normal mammary gland, MMPs orchestrate extensive reduc-
tive re-modelling in the later phase of involution via degrada-
tion of ECM, and MMP2, 3, 7, 9 and 11 are important to this
processing [59], which is probably driven by cytokine-
triggered ERK1/2 activity (see below) [60,61].
ERK1/2 activity has been highlighted in several studies of
invasion (reviewed in [62]). Cell-cell adhesion molecules
(including E-cadherins and tight junction proteins such as
ZO-1 (zona occludens 1)) play a pivotal role in maintaining
normal breast epithelial architecture. A hallmark of EMT is the
loss of E-cadherin expression and an increase in the expres-
sion of N-cadherin and vimentin. EGF-induced EGFR
activation destabilises E-cadherin adhesions [63]. However, it
is known from several studies that re-expression of E-
cadherin alone may not be sufficient to restore regulated cell
growth and epithelial-like behaviour. For example, in MCF10A
cells over-expressing activated Ras, restoration of an epithe-
lial cell phenotype required both the over-expression of
E-cadherin and the suppression of ERK1/2 activity [64].
Overexpression of N-cadherin in MCF-7 cells induces cell
migration in vitro and invasion and metastasis in vivo by an
ERK1/2-dependent mechanism [65,66].
Available online http://breast-cancer-research.com/content/11/5/209
Page 3 of 14
(page number not for citation purposes)Breast Cancer Research    Vol 11 No 5 Whyte et al.
Page 4 of 14
(page number not for citation purposes)
Table 1
Cell culture based experimental characterisation of ERK1/2 association with breast cancer pregression
Model Reference
ERK1/2 signalling
MEK1 signalling mediates transformation and metastasis EpH4 mammary epithelial cells [25]
RAF/MEK/ERK1/2 and PI3K/PTEN/AKT signalling pathways  Hematopoietic, breast (MCF7) and prostate  [22]
interact in breast cancer cancer cells
Three-dimensional organisation
MECs fail to organise as acini because of a persistent β1-integrin- HMT-3522 T-42 [75]
EGFR-ERK1/2 drive, but will form acini if β1-integrin, EGFR or ERK1/2 
function is inhibited 
Persistent activation of ERK1/2 impairs acinus formation and leads to invasion HC11 MECs [34]
Delayed activation of ERK1/2 impacts cell proliferation and ERα-mediated MCF7  [82]
transcription
Over-expressed Par6 acts in a complex with cdc42 and aPKC to induce  MECs [36]
hyperproliferation and generate multi-acinar structures in an ERK1/2-dependent 
fashion
Activation ofthe ERK1/2 blocks Bim expression andcorrelates with  MECs [37]
protection from luminal apoptosis
Invasion
Ha-Ras cooperates with TGFβ to induce EMT and Raf/ERK1/2 is required  Ha-Ras-transformed MECs in 3D  [40]
collagen/matrigel matrices
ERK1/2 signalling induces MMP expression and the duration of MAPK  Keratinocytes [53]
activation is an important determinant for certain growth factor-mediated functions
uPA binding to uPAR activates ERK1/2 and induces cell migration MCF7 [8]
uPA induces cell proliferation via ERK1/2 activation MDA-MB-231  [56]
uPA determines the basal level of activated ERK1/2 and prevents apoptosis  MDA-MB-231 [57]
Restoration of an epithelial phenotype requires both the over-expression of  MCF10A cells over-expressing activated Ras [64]
E-cadherin and the suppression of ERK1/2
Scribble co-operates with mutations in Ras and Raf to induce a migratory  MCF10A [67]
phenotype via induction of ERK1/2
ECM changes impact integrin signalling and can promote mitogenic signalling  Non-malignant and human breast tumour  [75]
through ERK1/2 cell line (T4-2)
ERK1/2 substrates, the Ets transcription factors, induce EMT and invasiveness  MECs [76-78]
‘Tumour-initiating cells’ can be derived from mammary cells following the  MECs [81]
activation of ERK1/2 and induction of EMT
ErbB/EGFR signalling to ERK1/2
Overexpression of ErbB2 induces EMT through ERK1/2 activation MCF10A [90]
Expression of ErbB2 induces anti-apoptotic proteins Survivin and Bcl-2  MCF7 [87]
via ERK1/2 and PI3K signalling 
Experimentally triggered ErbB2 activation protects against apoptosis and  MCF10A [88,89]
disrupts mammary epithelial cell organisation in an ERK1/2-dependent manner
Progesterone receptor, IGF-1, VEGF, growth hormone and a range of ligands  T47D, MECs [91]
require EGFR to induce ERK1/2 activation 
ER, tamoxifen resistance and ERK1/2 signalling
ERK1 and 2 are activated via oestrogen signalling through GPR30, MCF7, SKBR3 breast cancer cells [10]
resulting in transactivation of EGFR
EGFR or ErbB2 resistance correlated with high ERK1/2 and AKT activity Breast cancer cells [9]
Cell survival and cell death
Survival factor-induced ERK1/2 phosphorylates BIM, inhibiting its association  Haematopoietic cells [134]
with BAX and proapoptotic activity
ERK1/2 phosphorylates the pro-apoptotic BCL-2 family member BimEL, CC139  fibroblasts [132,133]
leading to its degradation by the proteasome
aPKC = atypical PKC; EGF = epidermal growth factor; EGFR = EGF receptor; EMT = epithelial-to-mesenchymal transition; ER = oestrogen
receptor; ERK = extracellular regulated kinase; IGF = insulin-like growth factor; MAPK = mitogen-activated protein kinase; MEC = mammary
epithelial cell; MMP = matrix-metalloproteinase; Par = Partitioning defect; PI3K = phosphoinositide 3-kinase; PTEN, phosphatase and tensin
homolog; TGF = transforming growth factor; uPA = Plasminogen activator, Urokinase; uPAR = Urokinase receptor; VEGF = vascular epidermal
growth factor.Polarity proteins (such as Par-, Crumbs- and Scribble-
complex proteins) determine the establishment and mainte-
nance of cell polarity in epithelial cells (as reflected, for
instance, by the asymmetric distribution of cadherin and tight
junctions). But they have been shown to redeploy and co-
operate in a sustained ERK1/2 signalling environment to
induce abnormal cell growth and invasive potential [36]. And,
suppressed expression of the polarity regulator Scribble in
MCF10A cells was found to co-operate with mutations in Ras
and Raf to induce a migratory phenotype via induction of
ERK1/2 (but not p38 or JNK) signalling [67].
Alongside a loss of cell-cell adhesions and polarity, cyto-
skeleton re-modelling and the formation of cellular protrusions
are a feature of breast cancer cell migration and early
metastasis. The dynamics and regulation of the actin
cytoskeleton is central to migratory processes and may be
corrupted at several levels in invasive cancers (reviewed in
[68]). Induced ERK1/2 signalling can inactivate integrin-
mediated cell adhesion and activate myosin light chain
kinase, thereby impacting cell migration [69]. Also central to
migratory processes are focal adhesion components, for
instance Focal adhesion kinase, which is activated by
integrins and by growth factor receptors, including the EGFR
family [70]. Focal adhesion kinase is hyper-activated during
the early stages of invasion responses in cultured breast
cancer cells and was found to both stimulate cell proliferation
[60] and inhibit apoptosis [71]. It is also hyper-activated in
ErbB2-positive breast cancers [72]. Interestingly, mice with
conditional Focal adhesion kinase knockout in the mammary
gland display decreased alveolar epithelial cell proliferative
capacity during late pregnancy, with reduced cyclin D1
expression and reduced ERK1/2 phosphorylation [73].
Another environmental cue, tissue rigidity (due to a stiffer
ECM), can promote tumour progression (reviewed in [74]).
ECM changes impact integrin signalling and can promote
mitogenic signalling through EGFR-ERK1/2 signalling and
also cell contractility through Rho, which can further increase
matrix stiffness [75], contributing to the cycle of tumour
growth and progression.
Key ERK1/2 substrates, the Ets-1 transcription factors, have
been shown to induce EMT and invasiveness in a series of
human breast cancer cell lines. The Ets-factor-ESE-1
transforms MCF-12A mammary cells in culture [76]. Ets-1
activity promotes breast cancer cell metastasis (and ERK1/2
signalling) by driving the expression of MMPs, FGF, uPA,
uPAR and EGF [77,78].
‘Cancer stem cells’ are potentially rare cells with both stem
and tumourigenic properties. They have an indefinite potential
for self-renewal and are hypothesised to drive tumourigenesis
[79]. The existence of a subpopulation of breast cancer stem
cells was demonstrated recently when they were isolated
from breast cancer pleural effusions by limiting dilution
transplantation of the cells into the mammary fat pad of
immuno-compromised mice [80]. ‘Tumour-initiating cells’ can
be derived from cultured mammary cells following the
activation of the ERK1/2 pathway and induction of EMT and
such cells are found in ErbB2-induced mammary tumours
[81,82]. While the capability of stimuli that drive EMT to
enhance the abundance of breast cancer stem cells is most
interesting and will provide a ready experimental model in
which to study their generation, the relevance of the
phenomenon to breast tumour progression remains to be
established.
ErbB/EGFR family signalling to ERK1/2
Of the growth factor receptors that input signals to ERK1/2
in breast tumour cells, the ErbB/EGFR family of receptor
tyrosine kinases is one of the major classes: they are
commonly over-expressed (for example, ErbB2 gene
amplification occurs in 20 to 30% of tumours [19]) or persis-
tently signal (for example, EGFR in tamoxifen resistance [83])
in human breast tumours. An anti-receptor antibody,
trastuzumab, is used with some success in treating disease
with amplified ErbB2; gefitinib, an EGFR kinase inhibitor, is
used to treat patients exhibiting tamoxifen resistance [84]. A
family of ten ligands, including EGF, amphiregulin and
heregulin, bind the ErbB receptors, induce receptor
dimerization, trigger kinase activity, autophosphorylation and
downstream activation of ERK1/2 and PI3K-AKT signalling.
There are four closely related ErbB receptors (ErbB1/EGFR,
ErbB2/Her-2/Neu, ErbB3 and ErbB4) that form hetero- or
homo-dimers. ErbB receptor signalling can increase cell
proliferation, decrease apoptosis and affect the survival and
motility of primary and metastatic breast tumour cells. ErbB2
action also enhances signalling interactions with the cellular
micro-environment and affects cell adhesion (reviewed in [85]).
The potential contribution of the ErbB receptor-ERK1/2
signalling has been widely studied in experimental model
systems of progression (reviewed in [19]). In a range of
breast cancer cell lines hyper-proliferation is mediated by
EGFR- or ErbB2-dependent ERK1/2 activation (reviewed in
[86]). ErbB2-ERK1/2 signalling may affect breast cancer cell
behaviour through influencing cell survival as much as
through affecting proliferation: expression of ErbB2 in MCF-7
cells induces the anti-apoptotic proteins Survivin and Bcl-2
via ERK1/2 and PI3K signalling [87], and experimentally
triggered ErbB2 activation protects against apoptosis and
disrupts MCF10A epithelial cell three-dimensional organisa-
tion in an ERK1/2-dependent manner [88,89]. Over-
expression of ErbB2 induces EMT through ERK1/2 activation
in MCF10A human breast epithelial cells [90]. While EGFR-
ERK1/2 signalling is conventionally ligand-activated, this may
often arise through an autocrine mechanism; MMP9 partially
acts to drive invasiveness through induction of EGF
expression [91]. Interestingly, in MCF10A and a range of
breast cancer cell lines, activation or over-expression of
ErbB2 has been shown to increase cell growth in vitro, to
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migration via up-regulation of MMP-9 (which may involve
autocrine EGFR activation). Common also is activation of this
signalling by EGFR trans-activation, which has been shown
to be induced by G-protein-coupled receptors [92,93].
Furthermore, in a single cell line insulin-like growth factor
(IGF)-1, vascular epidermal growth factor (VEGF), growth
hormone and a range of ligands all require EGFR to induce
ERK1/2 activation [91]. In addition, the progesterone
receptor was recently found to upregulate WNT-1 and to
induce EGFR transactivation and a sustained activation of
ERK1/2 in T47D cells growing in an adhesion-independent
fashion in soft agar [94].
Promoters that selectively drive gene expression in the
mammary gland (that is, those for mouse mammary tumour
virus (MMTV) and whey acidic protein) have allowed the
creation of useful mouse models for studying breast cancer in
vivo. The best characterised models are those expressing the
viral oncogene encoding the polyoma middle T antigen
(MMTV-PyV MT) as paradigm of viral transforming potential,
and that expressing ErbB2 (MMTV-Neu) [95,96]. A
complementation study that crossed tyrosine phosphatase
PTP1B knockout mice into this ErbB2 over-expression
background led to down-regulation of ERK1/2 signalling and
delayed tumour development, suggesting a role for the
ERK1/2 pathway in ErbB2-induced mammary tumourigenesis
[97,98]. A direct role for ERK1/2 in induction of mammary
tumour progression has been recently shown in vivo, using
cells transplanted into the mammary fat pad [99]. The authors
showed that ERK1/2 directly modulates the phosphorylation
and degradation of the tumour suppressor FOXO3a
(Forkhead box 3), leading to a decrease in the anti-
tumourigenic activity of this protein in the mammary gland.
Lastly, the EphA2 receptor tyrosine kinase, a regulator of
mammary gland branching morphogenesis [100], which
drives Ras-ERK1/2 and RhoA GTPase signalling, has been
shown to enhance tumour formation in MMTV-Neu mice, but
not in MMTV-PyV MT mice [101], again potentially linking the
ERK1/2 pathway to ErbB2-induced tumourigenesis.
Thus, in breast cancer, EGFR/ErbB receptors are commonly
over-expressed [19] or persistently signal (in tamoxifen resis-
tance [83]), and an anti-receptor antibody is being used with
success in treating disease with amplified ErbB2, and an
EGFR kinase inhibitor is being used to treat tamoxifen-
resistant disease [84]. In cell culture-based experimental
model systems it is clear, as outlined above, that a functional
link can be made between EGFR/ErbB receptor activation,
induction of ERK1/2 pathway signalling and relevant
outcomes such as increased proliferation [102], cell survival
[103] and induction of motility [16] and invasiveness [17].
But does this qualify the MEK1-ERK1/2 signalling pathway as
a useful therapeutic target in breast cancer, generally?
Available clinical evidence linking high activated ERK1/2
levels to a good disease outcome [26-28] would say no. But,
for instance, in a subset of cases where anti-EGFR therapy
fails there may be some potential [84]. But perhaps the most
useful experimental endeavour would be to develop additional
cell-based models to more accurately mimic progression of
particular disease subtypes in order to define the dominant
supporting intracellular signalling pathways and, thus, new
key therapeutic targets.
Oestrogen receptor, tamoxifen resistance and ERK1/2
signalling
The biological actions of oestrogen are mediated both by
transcriptional regulation (involving ERα and ERβ in the
nucleus) and by non-genomic actions via ligand binding to
ERα at the plasma membrane [104-106]. In addition, ERK1/2
phosphorylates ERα on sites in its amino-terminal ligand-
independent transcriptional activating domain (Ser118 and
Ser167) [83,107]. Ser167 is phosphorylated by AKT, p90
Ribosomal S6 kinase, and casein kinase II as well as by
ERK1/2 [108]. Phosphorylation on Ser118 by ERK1/2
increases the transcriptional activation function, thus providing
a means by which ERα can be activated in a ligand-
independent manner through growth factor receptor signal-
ling. It may also facilitate blocking of inhibitory actions of anti-
oestrogens/selective ER modulators on ERα in breast cancer
cells and, hence, contribute to tamoxifen resistance; the
phosphorylation event may act to reduce the binding of the
high affinity ligand, 4-hydroxy-tamoxifen, to ERα [83]. It has
been shown that ErbB2-over-expressing MCF-7 cells are
tamoxifen resistant; they have high levels of activated ERK1/2
and high levels of phosphorylation of ERα at Ser118 [109].
MEK inhibitors reverse this resistance [110]. But interest-
ingly, several studies have linked elevated levels of phos-
phorylation at Ser118 of ERα to a positive survival outcome
for breast cancer patients [26,111]. One study positively
correlates elevated levels of ERK1/2 activation with elevated
phosphorylation of ERα at Ser118 and with a good survival
outcome [26]; here also phosphorylation of ERα at Ser118
inversely correlated with ErbB2 expression, suggesting that
ErbB2 is not primarily signalling through ERK1/2 in this
context [83]. The relationship of phosphorylation at the other
ERK1/2 target, Ser167, to outcome for patients and to
tamoxifen resistance is less than clear; suffice it to say that
AKT rather than ERK1/2 would seem to be its major
generator [83].
ERK1 and ERK2 are also activated via oestrogen signalling
through the G-protein-coupled receptor GPR30, which
results in transactivation of EGFR in MCF-7 cells and in
SKBR3 breast cancer cells [10]. However, GPR30 may play
a broader role in balancing ERK1/2 activation as oestrogen
signalling via the G-protein-coupled receptor inhibits
ERK1/2 activity by a cAMP-dependent mechanism, which
results in Raf-1 inactivation in breast carcinoma cells [112].
It is implied that oestrogen may drive cellular responses that
are growth factor dependent via GPR30 in ER-negative
breast tumours [10].
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of ER gene expression, which is also tissue-specific
[113,114]. Post-translational modification by palmitoylation
recruits an abundant amino-terminally truncated ERα (46 kDa)
to the plasma membrane in human endothelial cells,
osteoblasts and MCF-7 cells [113,115,116]. ER46 mediates
rapid membrane-initiated oestrogen responses, including
activation of endothelial nitric oxide synthetase [116,117]. A
functional signalling node composed of ER46, c-Src and p85
(the regulatory subunit of PI3K) has been identified in the
oestrogen-induced activation of endothelial cells, and is
directed by c-Src [118]. The importance of the presence of
membrane associated isoforms of ER lie in their ability to illicit
rapid and non-transcriptional responses to oestrogen [114].
Anti-hormone treatment with selective ER modulators, most
commonly tamoxifen, act to inhibit ER activity in breast cancer
cells and their metastases; aromatase inhibitors block
oestrogen biosynthesis and reduce endogenous ligand-
dependent ER activation [83,119]. In suitable patient cohorts
both therapies prolong survival, but resistance to these
therapeutics limits their use [83]. In cell culture studies in
which EGFR or ErbB2 have been over-expressed and anti-
oestrogen resistance induced [120], or resistance induced
by prolonged exposure to anti-oestrogens [9,121], resistance
correlated with high ERK1/2 and AKT activity. There is
accumulating evidence that growth factor-triggered ERK1/2
signalling contributes significantly to tamoxifen resistance but
it may do so by multiple mechanisms. Firstly, both tamoxifen-
resistant tumours and cell lines tend to be rich in EGFR and
ErbB2 receptors and their activation of ERK1/2 and PI3K-
AKT would have significant anti-apoptotic effects. Secondly,
ERK1/2 phosphorylation of Ser118 in ERα may also
contribute to resistance [83]. And finally, non-nuclear ER
activity may contribute: the IGF receptor (IGF-1R) acts
upstream of ErbB1 in a signalling pathway in MCF-7 cells,
which mediates oestrogen activation of ERK1/2, with subse-
quent cell growth stimulation and protection against
apoptosis. Oestrogen stimulated the phosphorylation of both
IGF-1R and ErbB1, and inhibitor studies that blocked this
pathway also blocked ERK1/2 activation and the mitogenic
and anti-apoptotic effects of oestrogen [9].
The tamoxifen resistance phenotype is predominantly asso-
ciated with tumour re-growth rather than metastasis [83].
However, Santen and colleagues [3] comment that the
phenotype (potentially sustained by EGFR/ErbB2-ERK1/2/
PI3K-AKT signalling) is that that would promote invasion
and metastasis. Interestingly, when over-expressing Ras
mutants in NIH 3T3 fibroblasts to activate downstream
effectors (Raf-ERK1/2, PI3K or RalGEF) and, thereby,
tumour growth in nude mice, it was found that only the
mutant that activated ERK1/2 (V12S35 Ras expressed in
NIH 3T3 fibroblasts) also induced lung metastasis [122],
highlighting the potential importance of sustained ERK1/2
signalling in metastasis.
Pubertal mammary gland ductal morphogenesis in the mouse
requires epithelial cell ERα-induced EGFR ligand (amphiregulin)
expression, as indicated by knockout/mammary fat pad trans-
plantation studies [123]. Additional knockout/transplantation
studies indicated that the target for the amphiregulin was
stromal cell EGFR, without which the phased epithelial
proliferation and branching of mammary tree development
fails [124]. This relationship and its morphological outcome
contrasts with the ER-EGFR-family-ERK1/2 signalling inter-
actions seen in ‘ErbB2 amplified’ breast tumours and
tamoxifen-resistant disease, where we suppose a dominant
and sustained ERK1/2 signalling contributes. Additional
studies have demonstrated the presence of an ER-controlled
Src-ERK1/2 phosphorylation cascade functioning during
pubertal ductal morphogenesis [125].
Cell survival and cell death
Both ERK1/2 activation and its inhibition can induce apop-
tosis, with the output dependent on the cellular context and
input signalling. ERK1/2 plays a role in apoptosis induced by
a range of therapeutics in breast cancer cells. ERK1/2 and
p38 signalling was found to be required for resveratrol-
induced apoptosis in MDA-MB-231 breast cancer cells
[126,127] and activation of ERK1/2 and JNK, but not p38,
was found to be required for vitamin E succinate-induced
apoptosis of MDA-MB-435 breast cancer cells [128].
Genistein, Oligonol, kaempferol, and linoleic acid all induce
apoptosis in breast cancer cells in an ERK1/2-dependant
manner [129-131].
ERK1/2 phosphorylates the pro-apoptotic BCL-2 family
member BimEL (a BH3-only domain protein) [132], leading to
its degradation by the proteasome [133]. Bim initiates
apoptosis, but after survival factor-induced ERK1/2-
phosphorylation, Bim’s association with Bax is inhibited, as is
its pro-apoptotic activity, leading to cell survival [134]. As
outlined earlier, Bim drives cell death during lumen clearance
in the ductal terminal end buds of the developing pubertal
mammary tree and during acinus formation [37,39]. But
importantly, it drives the cell death of epithelial anoikis, whose
inhibition is permissive for invasion and metastasis [135].
ERK1/2 action, regulated by EGFR or coordinately by EGFR
and  β1-integrin, negatively regulates Bim activity both at a
transcriptional level and by phosphorylation; the former may
be the principal mode of regulation [37]. The related BH3-
only domain protein Bmf is expressed during involution, and is
active in epithelial cell anoikis (monolayer culture) and in
apoptosis/lumen clearance during acinus formation.
Sustained ERK1/2 or PI3K activation suppresses this Bmf
up-regulation, suggesting that, in this instance, active ERK1/2
was pro-survival [38]. Growth and survival factor-activated
ERK1/2 signalling can also regulate Hdm2 expression (a
negative regulator of p53), contributing to a pro-survival
effect [136]. p53 itself can activate ERK1/2 signalling via
transcriptional activation of the EGF gene [137]. Expression
of p53 in other circumstances can reduce phospho-ERK1/2
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apoptosis inducing factor-mediated apoptosis in MCF-7 cells
in response to metals [138]. The authors also found that
suppression of p53 in MDA-MB231 and MCF7-E6 cells
resulted in strong ERK1/2 phosphorylation.
Normal mammary gland involution is characterized by
extensive alveolar epithelial cell apoptosis in its initial stages,
and later by matrix degradation and tissue re-modelling
directed by matrix-degrading MMPs 2, 3, 7 and 11, the
plasminogen activation pathway and cathepsins (reviewed in
[59]). In conditional Stat3-/- mice involution is delayed [139].
Stat3 is thus pro-apoptotic. IL6 expression increases with the
onset of involution, and parallels the activation of Stat3 and
ERK1/2 [61,140]. Leukemia inhibitory factor also mediates
ERK1/2 activation at this time; however, sustained activation
of ERK1/2 through to late involution requires Oncostatin M. It
is suggested that the controlled re-modelling of mammary
tissue at involution is regulated by IL-6, leukemia inhibitory
factor and Oncostatin M, acting via ERK1/2 and by driving
expression of pro-apoptotic Bax [61].
p38, JNK and ERK5
p38
p38 MAPK plays roles in cell differentiation, growth inhibition
and apoptosis [141,142]. p38 MAPK is activated in cells in
response to stress signals, growth factors, inflammatory
cytokines, UV, heat and osmotic shock [142]. Its activation
often leads to cell death. In addition, a new role for p38 in
‘checkpoint control’ during cell division and cell survival is
now recognized [143]. Four isoforms of p38 exist (p38α, β, γ
and δ), although p38α is the most widely expressed. MKK3/6
(MAPKKK) and SEK (MAPKK) activate p38. p38 is also
activated via interactions with the scaffolding protein TAB1
[144]. Activated p38 phosphorylates and activates many
transcription factors (including Activating transcription factor-2,
Max, Myocyte enhancer factor-2, Mac, p53 and Stat1)
[145,146].
Links between p38 and invasiveness in cultured cells have
been reported: phospho-p38 is elevated in cultured invasive
breast cancer cells and constitutive p38 activity induces the
overproduction of the pro-invasive uPA [147]. Also, treatment
of the invasive BT549 breast cancer cells with a p38 MAPK
inhibitor diminished both uPA and uPAR expression and
inhibited the ability of these cells to invade matrigel
[147,148]. Furthermore, activated Src over-expression was
shown to necessarily activate p38 during TGFβ-induced
breast cancer cell proliferation and invasion [149]. Studies on
mammary cells indicate that WAVE-3 (a regulator of
cytoskeletal dynamics and cell motility) regulates breast
cancer progression, invasion and metastasis through the p38
pathway and MMP production. Knockdown of WAVE3 using
small interfering RNA in MDA-MB-231 cells decreases p38
activity but not AKT, ERK1/2 or JNK [150]. Elevated
phospho-p38 levels have been associated with high
expression of EGFR and ErbB2 as well in tamoxifen-resistant
xenografts [151]. p38 would not be seen as driving apoptosis
in this context; maybe it acts to support nuclear functions of
ER [152]. And interestingly, a relationship between p38 and
phospho-p38 levels and lymph node metastasis was
identified in human breast cancer samples [151]. Most
interestingly, in a study of matched primary and recurrent
tamoxifen-resistant tumours (and a parallel study of a mouse
xenograph model of tamoxifen resistance) an association of
phospho-p38 and elevated ErbB2 with tamoxifen resistance
was found [151].
JNK
JNKs 1, 2 and 3 are activated by MKK 4 and 7, which are
substrates of MAPKKKs (for example, MEKK1/2 or TGFβ-
activated kinase 1). JNK has a wide range of opposing
functions within cells but is best known for its role in trigger-
ing apoptosis after exposure to cellular and environmental
stresses [153]. Classically, JNK phosphorylates c-Jun,
leading to the binding of c-Jun to c-Fos and the activation of
activator protein-1 (AP-1), which can ultimately promote cell
proliferation [154].
JNK-supported proliferation has been reported for a number
of cultured breast cancer cell model systems; inhibition of
JNK resulted in cell cycle arrest during G2/M in three
different breast cancer cell lines, leading to DNA endoredupli-
cation (cellular DNA content greater than 4N), decreased
proliferation, and apoptosis [155]. In MCF-7 cells, JNK was
found to promote cell growth after induction by IGF-1 and a
presumed autocrine stimulation [156]. In both a clinical study
of matched pairs of ER-positive tamoxifen-sensitive and
tamoxifen-resistant human breast tumours [157] and a
xenograph model of tamoxifen resistance [158], a positive
association of activated/phosphorylated JNK with tamoxifen
resistance has been observed. In contrast, JNK action has
been reported to contribute in a number of independent ways
to the three-dimensional organisation of normal mammary
epithelial cells (that is, during acinus development). The
actions of glucocorticoids in supporting the patency of
mammary epithelial cell tight junction adhesions is well
described [159]. Murtagh and colleagues [160] showed that
glucocorticoids act to support such activities during
mammary epithelial acinus formation by activating JNK
signalling in a BRCA1-dependent manner. Inhibition of JNK
action during acinus formation blocks the establishment of
cell polarisation, the formation of tight junctions, the AP-1-
dependent expression of tight junction component proteins
and lumen clearance, allowing the formation of tumour-like
disordered assemblies of cells; the latter cascade of events is
ERK1/2-dependent and reversible with a MEK1 inhibitor (E
McArdle, unpublished observation). Interestingly, it has been
subsequently shown that c-Myc induces cell death in MCF-
10A cells during acinus formation by inducing formation of a
Scribble-bPIX-GIT1 complex that activates a Rac-JNK-c-Jun-
Bim apoptotic pathway. Inhibition of ERK1/2 in this context
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Myc specifically uses the JNK pathway to induce cell death in
ordered mammary epithelial cells [161]. These studies
emphasise the tumour-suppressor-like activities of the JNK
signalling pathway, at least in these cell culture model
systems.
ERK5
The fourth MAP kinase of interest in this context is ERK5 [2].
Relatively, it is of large molecular size [162], with its activation
being carried out by the MAPKK MEK5 [163], which is itself
activated by MEKK2 or 3 [164]. While distantly related to,
and sharing its mechanism of molecular action with, ERK1/2,
gene knockout studies in mice show ERK5 to have non-
redundant functions in heart development [165], vasculo-
genesis and angiogenesis [166] and endothelial cell survival
[166]. Cell culture based experiments have pointed to ERK5
functioning at a molecular level in mitosis [167] and cell
survival [168]. ERK5 is activated by growth factors [169],
integrin engagement [170] and cell stress [167], and its
important molecular targets would seem to include the
induction of transcription of components of the transcription
factor AP-1 (cJun [171] and Fos [172]) and activation of
transcription factors of the myocyte enhancer family group
(for example, MEF2C, a well characterised target [173]), and
cMyc [174]. Serum and glucocorticod kinase is an interesting
target kinase of ERK5 [175]; it may mediate cell survival
influences of ERK5 to cellular stress [176]. Interestingly, in
20% of a human breast tumour set analysed, ERK5 levels
were elevated and activated ERK5 (phospho-ERK5) was
detected in many of the tumours. High levels of ERK5 were
found to be an independent predictor of disease-free survival
in this cohort and was associated with poor disease outcome
[177]. Complementing these findings are, firstly, studies on
ERK5 knockdown (using short hairpin RNA) in a human
breast cancer cell line, which showed a sensitisation to the
effects of ErbB 2 inhibitors [177]; secondly, studies in human
breast cancer cell lines that associate constitutively active
ERK5 with induced ErbB2, 3 and 4 activation [178]; and,
thirdly, that such cells harbouring a dominant defective ERK5
show reduced proliferation rates, which may be due to failure
to activate ErbB2 [178].
Future perspectives
We still do not have a full understanding of the key contri-
butions made by MAPK signalling to the different stages of
mammary gland development. But the clues we have suggest
interesting possibilities: during pubertal ductal morpho-
genesis, quantitative temporal differences in ERK1/2 activity
may trigger the decision to branch [7]; ERK1/2 signalling may
be the final mediator of the proliferation associated with
alveogenesis, of which β1-integrin is a significant driver
[179]; glucocorticoid-JNK-cJun signalling may be the primary
driver of tight junction ‘closure’ required at the transition from
late pregnancy to lactation [160]; and JNK may also play a
role in ductal development in the terminal end bud at puberty
as judged from its role in other developmental epithelial
systems [180,181]. We await developments with interest. At
the other end of the scale is the challenge of benefiting from
the prognostic measurement of ‘activated MAPK’ (most
immediately activated ERK1/2 and ERK5) levels in breast
cancer. With anti-phospho-MAPK antibodies of good quality
available, robust measurements of ‘activated/phosphorylated-
MAPK’ can be made. However, this assesses potential rather
than actual MAPK activity. Future analyses where phospho-
MAPK levels are co-assessed with known molecular outputs
of MAPK action will provide a true measure of activity and will
be useful both from a prognostic point of view and in defining
therapeutic targets. Of great importance also are therapeutic
strategies that target the contribution of intracellular signal-
ling networks that support disease progression in human
breast cancer. It is suspected that signalling from over-
expressed ErbB2 through ERK1/2 contributes to disease
progression, but some studies suggest that signalling
pathways other than the ERK1/2 pathway may be of equal or
greater importance in tumours exhibiting ErbB2 over-
expression [26]. EGFR-ERK1/2 signalling plays a role in
disease progression in some forms of tamoxifen-resistant
disease [84], and VEGF receptor-ERK1/2 signalling has also
been linked to disease progression [26]. Currently, mono-
therapies that target the receptor or ERK1/2 activity are
predicted to be of limited value. Instead, combination
therapies that target growth factor receptors, multiple
signalling pathways and signalling targets point the way
forward [83,84]; an example of this would be an EGFR/
ErbB2 inhibitor plus a multi-signalling pathway inhibitor (for
example, the Ras farensyltransferase inhibitor, which blocks
ERK1/2 activation and mTor (mammalian target of rapamycin)
signals (or a Src inhibitor [182]) plus a ‘full oestrogen
antagonist’ (for example, fulvestrant)). Rapid development of
successful strategies in this area is keenly awaited.
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